الفهرس 
Title: Efficacy and safety of recombinant tissue plasminogen activator r (tpa) in acute ischemic stroke due to small vessel versus large vessel diseases
List Of ContentsOnly 14 pages are availabe for public view
 |  | from | 211 |  |  |
| | | from | 211 | | |
Abstract
Background:Acute ischaemic stroke accounts for approximately 80% of all strokes and intravenous alteplase is the only Food and Drug Administration (FDA)-approved thrombolytic agent for the treatment of acute ischemic stroke despite the risk of post thrombolysis bleeding .Aim of the Work: to evaluate the efficacy and safety of thrombolysis with intravenous recombinant human tissue plasminogen activator (r TPA) for ischemic stroke in small and large vessel diseases. Patients: and Methods:This study is a cross sectional study of total of 50 patients whose having either small or large vessel diseases and received IV r(TPA). Patients were recruited from stroke unite at Al Ain hospital, United Arab Emirates between June 2015 to July 2016 .Results :our results show that Small vessel disease was associated with a better outcome than large vessel disease with no mortality recorded among them ,There was positive correlation between post TPA bleeding and NIHSS at onset , NIHSS after 24 hours and onset of time to treatment in both groups. In large vessel group there was statistical significance between NIHSS at onset and favorable outcome and there was a strong positive correlation with statistically high significance between the degree of ICA stenosis in the large vessel disease group and mRS at 3 month